Latest Trials Latest NewsFAQ

ABBVIE

🇫🇷France

Country: 🇫🇷France

Ownership: -

Established: 2013-01-01

Employees: -

Market Cap: $346B

Website: http://www.abbvie.com

Clinical Trials

A Study to Evaluate the Effectiveness and Patient-Reported Outcome of Adalimumab in Patients With Moderate to Severe Plaque Psoriasis in China

Completed

Conditions: Psoriasis

First Posted Date: 2017-08-02

Last Posted Date: 2021-10-14

Lead Sponsor: AbbVie

Target Recruit Count: 181

Registration Number: NCT03236870

Locations: 🇨🇳
Traditional Chinese Medical Hospital of xinjiang uygur autonomous region /ID# 209183, Wulumuqi, Xinjiang, China
🇨🇳
The 7th People's Hospital of Shenyang /ID# 169829, Shenyang, China
🇨🇳
The Second Affiliated Hospital /ID# 169842, Hangzhou, Zhejiang, China

and more 12 locations

Efficacy and Safety of Glecaprevir/Pibrentasvir (ABT-493/ABT-530) in Treatment-Naive and Treatment-Experienced Asian Adults With Chronic Hepatitis C Virus Genotype (GT) 1 to GT6 Infection With Compensated Cirrhosis and With or Without Human Immunodeficiency Virus Co-Infection

Phase 3

Completed

Conditions: Hepatitis C Virus (HCV)

Interventions: Drug: Glecaprevir/Pibrentasvir

First Posted Date: 2017-08-01

Last Posted Date: 2019-11-21

Lead Sponsor: AbbVie

Target Recruit Count: 160

Registration Number: NCT03235349

Locations: 🇨🇳
Guangdong General Hospital /ID# 156827, Guangzhou, Guangdong, China
🇨🇳
The First Hosp of Jilin Univ /ID# 156825, Changchun, Jilin, China
🇨🇳
West China Hospital /ID# 156835, Chengdu, Sichuan, China

and more 31 locations

A Study Evaluating the Safety, Pharmacokinetics, and Anti-tumor Activity of ABBV-321 in Subjects With Advanced Solid Tumors Associated With Overexpression of the Epidermal Growth Factor Receptor (EGFR)

Phase 1

Completed

Conditions: Advanced Solid Tumors Cancer

Interventions: Drug: ABBV-321

First Posted Date: 2017-07-31

Last Posted Date: 2021-05-06

Lead Sponsor: AbbVie

Target Recruit Count: 62

Registration Number: NCT03234712

Locations: 🇺🇸
Highlands Oncology Group /ID# 166132, Springdale, Arkansas, United States
🇺🇸
University of California, Davis Comprehensive Cancer Center /ID# 215012, Sacramento, California, United States
🇺🇸
Lifespan Cancer Institute at Rhode Island Hospital /ID# 168600, Providence, Rhode Island, United States

and more 15 locations

A Study Evaluating Tolerability and Efficacy of Navitoclax Alone or in Combination With Ruxolitinib in Participants With Myelofibrosis

Phase 2

Active, not recruiting

Conditions: Myelofibrosis (MF)

Interventions: Drug: Navitoclax
Drug: Ruxolitinib

First Posted Date: 2017-07-19

Last Posted Date: 2024-06-27

Lead Sponsor: AbbVie

Target Recruit Count: 191

Registration Number: NCT03222609

Locations: 🇺🇸
University of Southern California /ID# 164095, Los Angeles, California, United States
🇺🇸
Dana-Farber Cancer Institute /ID# 162675, Boston, Massachusetts, United States
🇨🇦
Princess Margaret Cancer Centre /ID# 214483, Toronto, Ontario, Canada

and more 88 locations

A Study to Evaluate the Efficacy and Safety of Glecaprevir/Pibrentasvir (ABT-493/ABT-530) in Treatment-Naive and Treatment-Experienced, Non-Cirrhotic Asian Adults With Chronic Hepatitis C Virus Genotype (GT) 1 to GT6 Infection With or Without Human Immunodeficiency Virus Co-Infection

Phase 3

Completed

Conditions: Hepatitis C Virus (HCV)

Interventions: Drug: Glecaprevir/Pibrentasvir
Drug: Placebo

First Posted Date: 2017-07-19

Last Posted Date: 2019-12-23

Lead Sponsor: AbbVie

Target Recruit Count: 546

Registration Number: NCT03222583

Locations: 🇨🇳
The Third Affiliated Hospital Of Sun Yat-Sen University /ID# 156900, Guangzhou, Guangdong, China
🇨🇳
Xiangya Hospital Central South University /ID# 156901, Changsha, Hunan, China
🇨🇳
Jiangsu Province People's Hospital /ID# 156861, Nanjing, Jiangsu, China

and more 45 locations

Impact of AbbVie Care Patient Support Program on Clinical, Health Economic and Patient Reported Outcomes, in Crohn's Disease, Ulcerative Colitis, Rheumatoid Arthritis, Psoriatic Arthritis, Psoriasis and Axial Spondyloarthritis, in the Portuguese National Health Service

Completed

Conditions: Rheumatoid Arthritis (RA)
Non-radiographic Axial Spondyloarthritis
Ankylosing Spondylitis (AS)
Crohn's Disease
Ulcerative Colitis (UC)
Psoriatic Arthritis
Psoriasis

First Posted Date: 2017-07-19

Last Posted Date: 2020-02-24

Lead Sponsor: AbbVie

Target Recruit Count: 116

Registration Number: NCT03223012

Locations: 🇵🇹
Instituto Portugues De Reumatologia /ID# 205963, Lisbon, Lisboa, Portugal
🇵🇹
CCA Braga - Hospital de Braga /ID# 201323, Braga, Portugal
🇵🇹
Centro Hosp de Tondela-Viseu /ID# 203775, Viseu, Portugal

and more 12 locations

A Study to Evaluate the Efficacy and Safety of Glecaprevir (GLE)/Pibrentasvir (PIB) in Treatment-Naive Adults in Brazil With Chronic Hepatitis C Virus (HCV) Genotype 1 - 6 Infection

Phase 3

Completed

Conditions: Hepatitis C Virus (HCV)

Interventions: Drug: Glecaprevir/Pibrentasvir

First Posted Date: 2017-07-17

Last Posted Date: 2020-03-17

Lead Sponsor: AbbVie

Target Recruit Count: 100

Registration Number: NCT03219216

Locations: 🇧🇷
Hospital de Clinicas de Porto Alegre /ID# 163167, Porto Alegre, Rio Grande Do Sul, Brazil
🇧🇷
Hospital Ernesto Dornelles /ID# 163171, Porto Alegre, Rio Grande Do Sul, Brazil
🇧🇷
Hospital de Clinicas de Porto Alegre /ID# 163166, Porto Alegre, Rio Grande Do Sul, Brazil

and more 11 locations

A Study Comparing the Safety and Efficacy of Risankizumab to Methotrexate in Subjects With Moderate to Severe Plaque Psoriasis

Phase 3

Completed

Conditions: Psoriasis

Interventions: Drug: methotrexate
Drug: risankizumab

First Posted Date: 2017-07-17

Last Posted Date: 2022-11-03

Lead Sponsor: AbbVie

Target Recruit Count: 104

Registration Number: NCT03219437

Locations: 🇧🇷
CETI - Centro de Estudos em Terapias Inovadoras /ID# 208593, Curitiba, Parana, Brazil
🇧🇷
PUC Trials-Nucleo de Pesquisa clinica da Escola de Medicina da PUCPR /ID# 164401, Curitiba, Parana, Brazil
🇧🇷
Unidade de Pesquisa Clínica da Faculdade de Medicina de Botucatu /ID# 164743, Botucatu, Sao Paulo, Brazil

and more 8 locations

Efficacy and Safety of 8-weeks of Glecaprevir/Pibrentasvir in Treatment-Naïve Adults With HCV Genotype 1-6 and Aspartate Aminotransferase to Platelet Ratio Index (APRI) ≤1

Phase 3

Completed

Conditions: Hepatitis C Virus (HCV)

Interventions: Drug: Glecaprevir/Pibrentasvir

First Posted Date: 2017-07-11

Last Posted Date: 2019-09-04

Lead Sponsor: AbbVie

Target Recruit Count: 230

Registration Number: NCT03212521

Locations: 🇺🇸
Univ Maryland School Medicine /ID# 161157, Baltimore, Maryland, United States
🇺🇸
Digestive Disease Associates - Baltimore /ID# 161260, Baltimore, Maryland, United States
🇺🇸
University of Vermont Medical Center /ID# 161263, Burlington, Vermont, United States

and more 39 locations

A Clinical Study to Evaluate the Safety and Efficacy of Elagolix in Participants With Moderate to Severe Endometriosis-Associated Pain

Phase 3

Completed

Conditions: Endometriosis

Interventions: Drug: Placebo for Elagolix
Drug: Estradiol/Norethindrone Acetate
Drug: Elagolix
Drug: Placebo for E2/NETA

First Posted Date: 2017-07-11

Last Posted Date: 2024-12-20

Lead Sponsor: AbbVie

Target Recruit Count: 681

Registration Number: NCT03213457

Locations: 🇺🇸
Clinical Research Adv, Inc. /ID# 149257, Puyallup, Washington, United States
🇺🇸
Tidewater Clinical Research /ID# 145397, Virginia Beach, Virginia, United States
🇺🇸
Atlanta Women's Research Inst /ID# 145543, Atlanta, Georgia, United States

and more 194 locations

© Copyright 2025. All Rights Reserved by MedPath

Home Terms & Conditions Privacy Policy